Hohimer Wealth Management LLC Acquires 20,038 Shares of Novo Nordisk A/S $NVO

Hohimer Wealth Management LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 240.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,382 shares of the company’s stock after purchasing an additional 20,038 shares during the period. Hohimer Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,575,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of NVO. True Wealth Design LLC grew its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares in the last quarter. NewSquare Capital LLC lifted its position in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares in the last quarter. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S in the third quarter worth $25,000. Strengthening Families & Communities LLC purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at $30,000. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $39,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Large Vivtex collaboration expands Novo’s push into oral obesity/diabetes medicines, which could widen patient access and reduce dependency on injectables — a long‑term growth signal. Novo Nordisk Pipelines Oral Obesity Drugs
• Positive Sentiment: Strong phase‑2 China data for triple‑agonist UBT251 (nearly ~20% weight loss reported) supports Novo’s broader pipeline beyond GLP‑1 and bolsters future product optionality. China UBT251 Trial
• Positive Sentiment: Several bullish commentary pieces argue the sell‑off overstates fundamental damage: oral Wegovy adoption and expanded Medicare coverage are cited as durable demand drivers and cash‑flow support. Why I’m Still Bullish On Novo
• Neutral Sentiment: Short interest fell meaningfully in February, reducing one immediate source of potential downside pressure (fewer forced covers), but overall market sentiment remains mixed.
• Neutral Sentiment: Broader market rotation into defensive names and sector dynamics are influencing trading — Novo’s large market cap and dividend yield make it sensitive to flows unrelated to biotech fundamentals.
• Negative Sentiment: Multiple analyst downgrades and lowered price targets this week prompted selling and contributed directly to intraday weakness; investors are focused on near‑term U.S. price compression and margin implications. Analyst Downgrade — American Banking News
• Negative Sentiment: Pomerantz law‑firm investor alert / investigation increases legal risk and uncertainty for shareholders, which typically depresses sentiment until clarity arrives. Pomerantz Investor Alert
• Negative Sentiment: Market reaction shows concern that large deals (Vivtex) and pipeline expansion may pressure near‑term margins and raise execution questions — some headlines explicitly note the stock dipped after the Vivtex announcement. Stock Dipped After Vivtex Deal

Novo Nordisk A/S Stock Down 0.3%

NVO stock opened at $37.50 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company’s 50 day moving average is $52.75 and its 200 day moving average is $52.85. The stock has a market cap of $167.42 billion, a price-to-earnings ratio of 10.81 and a beta of 0.67. Novo Nordisk A/S has a 1-year low of $37.31 and a 1-year high of $91.90.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Analysts Set New Price Targets

Several research analysts have commented on NVO shares. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. Morgan Stanley reissued an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. CICC Research began coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Finally, Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.